regardless of promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from PBMs. These insurers are often creating limitations to access, like steep price criteria and approval processes that restrict consumer opportunity. Analysts believe that th